Payment overview · 2025
General Payments
$141.10
7 reported records · 4 companies
Healthcare provider profile · identity verified
Allison J Geier, MD
Allopathic & Osteopathic Physicians|Family Medicine · WATERTOWN, SD · NPI 1629290440
Verified facts
What the public records show
CMS Open Payments records show Allison J Geier, MD received $141.10 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 51.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.12 | 51.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.19 | 26.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.71 | 11.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.08 | 10.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $141.10 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $73.12 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $73.12 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 107 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
107 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 696 | 149 |
| Atorvastatin Calcium | Atorvastatin Calcium | 387 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 352 | 83 |
| Lisinopril | Lisinopril | 328 | 77 |
| Omeprazole | Omeprazole | 310 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 291 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 59 |
| Losartan Potassium | Losartan Potassium | 236 | 53 |
| Gabapentin | Gabapentin | 197 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 42 |
| Potassium Chloride | Potassium Chloride | 164 | 31 |
| Furosemide | Furosemide | 159 | 32 |
| Simvastatin | Simvastatin | 156 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 30 |
| Alendronate Sodium | Alendronate Sodium | 137 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 125 | 23 |
| Donepezil Hcl | Donepezil Hcl | 116 | 13 |
| Warfarin Sodium | Warfarin Sodium | 108 | 19 |
| Eliquis | Apixaban | 107 | 24 |
| Sertraline Hcl | Sertraline Hcl | 106 | 27 |
| Tramadol Hcl | Tramadol Hcl | 98 | 28 |
| Mirtazapine | Mirtazapine | 97 | 14 |
| Metformin Hcl Er | Metformin Hcl | 87 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 16 |
| Metformin Hcl | Metformin Hcl | 81 | 21 |
| Carvedilol | Carvedilol | 78 | 15 |
| Montelukast Sodium | Montelukast Sodium | 71 | 20 |
| Prednisone | Prednisone | 71 | 35 |
| Famotidine | Famotidine | 70 | 13 |
| Spironolactone | Spironolactone | 70 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 18 |
| Alprazolam | Alprazolam | 61 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 55 | 16 |
| Pregabalin | Pregabalin | 49 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 16 |
| Methenamine Hippurate | Methenamine Hippurate | 47 | suppressed |
| Cephalexin | Cephalexin | 46 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 36 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 19 |
| Nitroglycerin Patch | Nitroglycerin | 38 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Allopurinol | Allopurinol | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Cefdinir | Cefdinir | 27 | 22 |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 18 |
| Lovastatin | Lovastatin | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 15 |
| Sucralfate | Sucralfate | 23 | suppressed |
| Meloxicam | Meloxicam | 22 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Repatha Syringe | Evolocumab | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 12 |
| Digoxin | Digoxin | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Nystatin | Nystatin | 16 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Simbrinza | Brinzolamide/Brimonidine Tart | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $141.10 · 7 records | ABBVIE INC. | ELIQUIS, EVENITY, FREESTYLE LIBRE 3, NURTEC ODT, QULIPTA, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error